UA127763U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, studies of low and high density lipoprotein cholesterol levels, arteriography, determination of eNOS T786C gene polymorphism in serum, osteocalcin content, TGF- (1, COMST. / ml, TGF- (1 <14 ng / ml, COMP> 595 ng / ml diagnose the development of atherosclerosis.

Description

A useful model belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography of I.N. Okorokov. Diagnosis of diseases of internal organs. - T. 6-S. 75-85.

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the method of developmental diagnostics, which includes the study of low and high-density lipoprotein cholesterol levels, arteriography, according to a useful model, in the blood serum of the patient to determine the polymorphism of the nitric oxide synthase gene (eMmO5 T786C), the content of osteocalcin, transforming growth factor beta 1 (TGF-VI1), cartilage oligomeric matrix protein (COMP). With homozygous carrier 786-SS, levels of osteocalcin "21 ng/ml, TFR-VD1" 14 ng/ml, SOMR "595 ng/ml diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the patient's blood serum, the polymorphism of the eMmoz 17786C gene is determined, the content of osteocalcin is determined by the enzyme immunoassay method,

TFR-VI, SOMR. With homozygous carrier 786-SS, levels of osteocalcin "21 ng/ml, TFR-81514 ng/ml, SOMR "595 ng/ml diagnose the development of atherosclerosis.

A specific example of using the method.

Patient B., 49 years old, was hospitalized in the clinic with a diagnosis of rheumatoid arthritis.

Examined Low and high density lipoprotein cholesterol levels were studied. Arteriography was performed. No signs of atherosclerosis were found. The emo T786C gene polymorphism was determined in blood serum. The content of osteocalcin, TGF-B1, and SOMP was determined by immunoenzymatic method.

Homozygous carrier 786-SS was established. Levels of osteocalcin - 16.5 ng/ml, TGF-B1 - 8.4 ng/ml,

SMR - 645 ng/ml. The development of atherosclerosis was diagnosed. Arteriographic confirmation

The diagnosis was received only after 12 months.

Thus, the proposed method is useful and allows establishing a diagnosis at an early date.

Claims (1)

USEFUL MODEL FORMULA The method of diagnosing the development of atherosclerosis, which includes a clinical examination, research on the levels of low and high-density lipoprotein cholesterol, arteriography, which is distinguished by the fact that the polymorphism of the eMoO5 gene T786C, the content of osteocalcin, TFR-RI1, COMP, in homozygous carriers of 786-СС are determined in the blood serum , levels of osteocalcin "21 ng/ml, TGF-DI1 "14 ng/ml, SMR »595 ng/ml diagnoses the development of atherosclerosis.